Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 14/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13067988 | 0.81 | IL2 (0.47) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL15249596 | 0.81 | IL2 (0.56) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL2886416 | 0.81 | IL2 (0.52) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL8235702 | 0.80 | IL2 (0.44) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL5030848 | 0.78 | IL2 (0.53) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL5027397 | 0.78 | IL2 (0.51) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL8234996 | 0.77 | IL2 (0.52) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL8227596 | 0.76 | IL2 (0.44) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL8237722 | 0.73 | IL2 (0.48) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL5033790 | 0.73 | IL2 (0.48) | IL2TNFSTIM1ORAI1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007087429-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | AHR, NFATC1, ICOS | IL2 6/4885TNF 146/4885STIM1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.